Clinical Trials
76 trialsNCT05413044 2025-12-08
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Bristol-Myers Squibb
Completed
NCT05421442 2025-12-08
DANBIO
Bristol-Myers Squibb
Completed
NCT01351805 2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA Completed
NCT03649061 2025-06-19
CareRA2020
Universitaire Ziekenhuizen KU Leuven
Phase 4 Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT06656169 2025-05-01
Effect of Subcutaneous Polyvidone Collagen Treatment on Hand Recovery in Adult Rheumatoid Arthritis.
Instituto Mexicano del Seguro Social
Phase 1/2 Completed
NCT01086059 2025-01-28
OTIS Humira Pregnancy Registry
University of California, San Diego
Completed
NCT05090124 2025-01-14
REALISE
NHS Greater Glasgow and Clyde
Phase NA Completed
NCT03016013 2024-09-26
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
Phase 3 Completed
NCT01242488 2024-07-17
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT05447182 2024-02-05
PPM:RANT
Brigham and Women's Hospital
Completed
NCT05215509 2024-02-02
RABEX
Rigshospitalet, Denmark
Phase NA Completed
NCT03120949 2023-10-12
CREDO 4
R-Pharm
Phase 3 Completed
NCT02760433 2023-09-21
CREDO 3
R-Pharm
Phase 3 Completed
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT02742597 2023-03-17
PACEinMM-ON
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT00048321 2022-12-05
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Ionis Pharmaceuticals, Inc.
Phase 2 Completed
NCT02789800 2022-11-03
PACEinMM-QC
Université de Sherbrooke
Phase NA Completed
NCT04952896 2022-11-02
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
Peking University Third Hospital
Completed
NCT03589833 2022-10-25
YISTAR
Peking Union Medical College Hospital
Phase 4 Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT03670667 2022-05-18
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
Bristol-Myers Squibb
Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT03663829 2022-03-09
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
Bristol-Myers Squibb
Completed
NCT02538341 2021-11-23
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
University of Alabama at Birmingham
Phase 2 Completed
NCT04529902 2021-11-23
DREAM
Brigham and Women's Hospital
Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01764321 2020-12-22
NexT
UCB Pharma
Completed
NCT01548768 2020-11-27
RHYTHM
Columbia University
Phase 4 Completed
NCT03941184 2020-11-23
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Mayo Clinic
Completed
NCT03348046 2020-03-04
PASSRRA
Hikma Pharmaceuticals LLC
Completed
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT01721044 2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3 Completed
NCT01590966 2019-08-26
SCINTRA
University Hospital, Ghent
Phase 3 Completed
NCT02475486 2019-06-26
ANSRA
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Completed
NCT00094562 2019-01-18
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT03736044 2018-11-08
Reconstitution of CD4+CD25highCD127low/-Tcell
University Hospital of Ferrara
Phase NA Completed
NCT02679001 2018-07-26
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
Hoffmann-La Roche
Completed
NCT02440906 2017-10-03
WIN
University of Florida
Phase NA Completed
NCT00503425 2017-08-15
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Hoffmann-La Roche
Phase 3 Completed
NCT01362062 2017-08-02
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hoffmann-La Roche
Completed
NCT00185848 2017-03-14
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Stanford University
Phase 1 Completed
NCT01351480 2017-03-13
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
Arthritis & Rheumatic Disease Specialties Research
Phase 3 Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed